AR074854A1 - Compuestos de plasmalogenos, composiciones farmaceuticas que los comprenden, su uso para tratar enfermedades del envejecimiento, procedimiento e intermediarios para su sintesis. - Google Patents
Compuestos de plasmalogenos, composiciones farmaceuticas que los comprenden, su uso para tratar enfermedades del envejecimiento, procedimiento e intermediarios para su sintesis.Info
- Publication number
- AR074854A1 AR074854A1 ARP090105048A ARP090105048A AR074854A1 AR 074854 A1 AR074854 A1 AR 074854A1 AR P090105048 A ARP090105048 A AR P090105048A AR P090105048 A ARP090105048 A AR P090105048A AR 074854 A1 AR074854 A1 AR 074854A1
- Authority
- AR
- Argentina
- Prior art keywords
- chch2ch
- chch2
- ch3ch2
- reduction
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 abstract 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract 1
- NXDDNODAJKZARA-UHFFFAOYSA-N 4-(dimethylazaniumyl)-3-hydroxybutanoate Chemical compound CN(C)CC(O)CC(O)=O NXDDNODAJKZARA-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- RDHQFKQIGNGIED-QMMMGPOBSA-N O-acetyl-D-carnitine Chemical compound CC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-QMMMGPOBSA-N 0.000 abstract 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 abstract 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000013566 Plasminogen Human genes 0.000 abstract 1
- 108010051456 Plasminogen Proteins 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004203 carnitine Drugs 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 229960003624 creatine Drugs 0.000 abstract 1
- 239000006046 creatine Substances 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 229950006137 dexfosfoserine Drugs 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 abstract 1
- 235000019136 lipoic acid Nutrition 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 abstract 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960002663 thioctic acid Drugs 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
En este documento se describen rutas de síntesis y usos terapéuticos de derivados de 1-alquil, 2-acil glicerol de la formula 1: los cuales cuando se administran a sistemas biológicos de mamíferos resultan en concentraciones celulares aumentadas de plasmalógenos sustituidos con etanolamina específicos para sn-2 independientemente de la capacidad de síntesis de éter lípido del sistema. El elevar niveles de las especies sustituidas específicamente en sn-2 de esta manera puede causar la reducción de los niveles de colesterol de membrana y la reducción de secreción de amiloide, Estos compuestos se pueden utilizar para el tratamiento o prevención de enfermedades del envejecimiento asociadas con aumento en colesterol de membrana, aumento en amiloide, y reducción en niveles de plasmalógeno, tales como neurodegeneración (incluyendo enfermedad de Alzheimer, enfermedad de Parkinson y degeneración macular relacionada con la edad), deficiencia cognitiva, demencia, cáncer (por ejemplo, canceres de próstata, pulmón, senos, ovarios y rinón), osteoporosis, desorden bipolar y enfermedades vasculares (tales como ateroesclerosis, hipercolesterolemia). Reivindicación 1: Un compuesto de acuerdo con la estructura de la fórmula 1: en donde: R1 y R2 son los mismos o diferentes y se seleccionan de una cadena de hidrocarburos de alquilo o alquenilo seleccionada de un grupo que consiste de: CH3(CH2)3-, CH3(CH2)5-, CH3(CH2)7-, CH3(CH2)9-, CH3(CH2)11-, CH3(CH2)13-, CH3(CH2)15-, CH3(CH2)17-, CH3(CH2)19-, CH3(CH2)21-, CH3(CH2)23-, CH3(CH2)3CH=CH(CH2)7-, CH3(CH2)5CH=CH(CH2)7-, CH3(CH2)7CH=CH(CH2)7-, CH3(CH2)4CH=CHCH2CH=CH(CH2)7-, CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)7-, CH3CH2(CH=CH)-, CH3(CH2)3(CH=CH)-, CH3(CH2)5(CH=CH)-, CH3(CH2)7(CH=CH)-, CH3(CH2)9(CH=CH)-, CH3(CH2)11(CH=CH)-., CH3(CH2)13(CH=CH)-, CH3(CH2)15(CH=CH)-, CH3(CH2)17(CH=CH)-, CH3(CH2)19(CH=CH)-, CH3(CH2)21(CH=CH)-, CH3(CH2)3CH=CH(CH2)5(CH=CH)-, CH3(CH2)5CH=CH(CH2)5(CH=CH)-, CH3(CH2)7CH=CH(CH2)5(CH=CH)-, CH3(CH2)4CH=CHCH2CH=CH(CH2)5(CH=CH), CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)5(CH=CH)-, CH3(CH2)3CH=CH(CH2)7-, CH3(CH2)5CH=CH(CH2)7-, CH3(CH2)7CH=CH(CH2)7-, CH3(CH2)4(CH=CHCH2)2(CH2)6-, CH3CH2(CH=CHCH2)3(CH2)6-, CH3(CH2)4(CH=CHCH2)4(CH2)2-, CH3CH2(CH=CHCH2)5(CH2)2-, CH3(CH2)7CH=CH(CH2)11, y CH3CH2(CH=CHCH2)6CH2-; R3 es un grupo seleccionado de ácidos grasos, carnitina, acetil-D/L-carnitina, tiocarnitina, acetil-D/L-tiocarnitina, creatina, norcarnitina, fosfocolina, ácido lipoico, ácido dihidrolipoico, fosfoetanolamina, fosfoserina, N-acetilcisteina, grupos de aminoácidos sustituidos o no sustituidos y grupos de las estructuras que se muestran a continuación: R4 y R5 son independientemente hidrógeno o alquilo menor; R6 es hidrógeno o alquilo menor; y R7 y R8 son independientemente hidrógeno o alquilo menor, incluye racematos o estereoisómeros aislados y sales o ésteres farmacéuticamente aceptables de los mismos. Reivindicación 41: Un compuesto de acuerdo con la estructura de a fórmula 2: en donde R1 y R4 a R8 son como se describieron en la reivindicación 1 y R9 es un grupo bloqueador, e incluyen racematos o estereoisómeros aislados y sales o ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13969508P | 2008-12-22 | 2008-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074854A1 true AR074854A1 (es) | 2011-02-16 |
Family
ID=42286823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090105048A AR074854A1 (es) | 2008-12-22 | 2009-12-22 | Compuestos de plasmalogenos, composiciones farmaceuticas que los comprenden, su uso para tratar enfermedades del envejecimiento, procedimiento e intermediarios para su sintesis. |
| ARP190101307A AR117572A2 (es) | 2008-12-22 | 2019-05-16 | Compuestos de plasmalógenos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101307A AR117572A2 (es) | 2008-12-22 | 2019-05-16 | Compuestos de plasmalógenos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9334235B2 (es) |
| EP (1) | EP2382201B1 (es) |
| JP (2) | JP5740312B2 (es) |
| KR (1) | KR101810988B1 (es) |
| CN (2) | CN102369193B (es) |
| AR (2) | AR074854A1 (es) |
| AU (1) | AU2009329784B2 (es) |
| BR (1) | BRPI0922619A8 (es) |
| CA (1) | CA2746831C (es) |
| IL (1) | IL213409A0 (es) |
| MX (1) | MX350291B (es) |
| MY (1) | MY169797A (es) |
| RU (1) | RU2546108C2 (es) |
| SG (1) | SG172340A1 (es) |
| TW (1) | TWI475989B (es) |
| UY (1) | UY32359A (es) |
| WO (1) | WO2010071988A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012519199A (ja) * | 2009-03-04 | 2012-08-23 | ネステク ソシエテ アノニム | 哺乳動物における内因性プラスマローゲンレベルを上昇させる方法 |
| CA2797960A1 (en) | 2009-10-01 | 2011-04-07 | Phenomenome Discoveries Inc. | Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis |
| JP5934483B2 (ja) * | 2011-09-05 | 2016-06-15 | 学校法人帝京大学 | リン脂質結合型ｄｈａ増加剤 |
| JP5997887B2 (ja) * | 2011-09-05 | 2016-09-28 | 学校法人帝京大学 | 経口投与剤 |
| WO2015064960A1 (ko) | 2013-10-29 | 2015-05-07 | 울산대학교 산학협력단 | 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물 |
| WO2016041013A1 (en) * | 2014-09-16 | 2016-03-24 | Baker Idi Heart And Diabetes Institute Holdings Limited | Glycerolipids and uses therefor |
| CN108276438B (zh) * | 2018-02-02 | 2020-05-22 | 中国海洋大学 | 一种epa缩醛磷脂的制备方法及其应用 |
| KR20210005190A (ko) | 2018-04-27 | 2021-01-13 | 가부시키가이샤 레오로지 키노쇼쿠힝겐큐죠 | 신규 플라스말로젠 유도체 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| CN112321446A (zh) * | 2020-11-25 | 2021-02-05 | 华南理工大学 | 一种酰胺衍生物的合成方法 |
| CN113150270A (zh) * | 2021-03-19 | 2021-07-23 | 广东丁沃生医疗器械有限公司 | 一种磷脂聚合物及其制备方法与应用 |
| JPWO2023027021A1 (es) * | 2021-08-23 | 2023-03-02 | ||
| WO2024111529A1 (ja) * | 2022-11-21 | 2024-05-30 | 株式会社 レオロジー機能食品研究所 | 脳プラズマローゲン増加剤、脳プラズマローゲン増加用経口組成物及び化合物の使用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4827011A (en) * | 1984-12-10 | 1989-05-02 | American Cyanamid Company | Antihypertensive phosphate derivatives |
| FR2736265B1 (fr) | 1995-07-07 | 1997-09-26 | Forgeot Marcel | Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| JP2004026803A (ja) | 2002-03-29 | 2004-01-29 | Nof Corp | 神経細胞死予防剤 |
| US20080020472A1 (en) | 2005-11-22 | 2008-01-24 | Frantz Biomarkers, Llc | Method for detecting an inflammatory disease or cancer |
| CA2689848A1 (en) | 2006-02-28 | 2007-09-07 | Phenomenome Discoveries Inc. | Methods for the diagnosis of dementia and other neurological disorders |
| US20080021000A1 (en) | 2006-07-19 | 2008-01-24 | Su Chen | Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species |
| JP2008125365A (ja) * | 2006-11-16 | 2008-06-05 | Kagoshima Univ | 高純度プラスマローゲン調製法 |
| EP2123281A1 (en) * | 2007-01-30 | 2009-11-25 | Tohoku University | Composition for prevention or treatment of disease associated with amyloidosis through inhibition of aggregation amyloid protein and through promotion of degradation of amyloid protein |
| AU2007346587C1 (en) | 2007-02-08 | 2015-01-22 | Med-Life Discoveries Lp | Methods for the treatment of Senile Dementia of the Alzheimer's Type |
| US20100105101A1 (en) | 2007-04-13 | 2010-04-29 | Phenomenome Discoveries Inc. | Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging |
-
2009
- 2009-12-16 TW TW098143152A patent/TWI475989B/zh active
- 2009-12-18 BR BRPI0922619A patent/BRPI0922619A8/pt not_active Application Discontinuation
- 2009-12-18 AU AU2009329784A patent/AU2009329784B2/en active Active
- 2009-12-18 RU RU2011124579/04A patent/RU2546108C2/ru active
- 2009-12-18 MY MYPI2011002904A patent/MY169797A/en unknown
- 2009-12-18 EP EP09833973.2A patent/EP2382201B1/en active Active
- 2009-12-18 SG SG2011045994A patent/SG172340A1/en unknown
- 2009-12-18 KR KR1020117015617A patent/KR101810988B1/ko not_active Application Discontinuation
- 2009-12-18 CN CN200980157183.5A patent/CN102369193B/zh active Active
- 2009-12-18 US US13/141,035 patent/US9334235B2/en active Active
- 2009-12-18 WO PCT/CA2009/001853 patent/WO2010071988A1/en active Application Filing
- 2009-12-18 JP JP2011541046A patent/JP5740312B2/ja active Active
- 2009-12-18 MX MX2011006795A patent/MX350291B/es active IP Right Grant
- 2009-12-18 CA CA2746831A patent/CA2746831C/en active Active
- 2009-12-18 CN CN201610221350.XA patent/CN105859680A/zh active Pending
- 2009-12-22 UY UY0001032359A patent/UY32359A/es not_active Application Discontinuation
- 2009-12-22 AR ARP090105048A patent/AR074854A1/es active IP Right Grant
-
2011
- 2011-06-06 IL IL213409A patent/IL213409A0/en active IP Right Grant
-
2015
- 2015-03-16 JP JP2015052549A patent/JP2015145388A/ja active Pending
-
2019
- 2019-05-16 AR ARP190101307A patent/AR117572A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009329784B2 (en) | 2016-08-25 |
| WO2010071988A1 (en) | 2010-07-01 |
| EP2382201B1 (en) | 2022-08-24 |
| EP2382201A1 (en) | 2011-11-02 |
| CN102369193B (zh) | 2016-05-04 |
| AU2009329784A1 (en) | 2011-07-07 |
| AR117572A2 (es) | 2021-08-18 |
| UY32359A (es) | 2010-05-31 |
| US9334235B2 (en) | 2016-05-10 |
| US20120035250A1 (en) | 2012-02-09 |
| MY169797A (en) | 2019-05-15 |
| JP2012512816A (ja) | 2012-06-07 |
| JP5740312B2 (ja) | 2015-06-24 |
| TW201034662A (en) | 2010-10-01 |
| JP2015145388A (ja) | 2015-08-13 |
| MX350291B (es) | 2017-09-04 |
| TWI475989B (zh) | 2015-03-11 |
| BRPI0922619A2 (pt) | 2016-09-13 |
| BRPI0922619A8 (pt) | 2023-01-10 |
| CN102369193A (zh) | 2012-03-07 |
| IL213409A0 (en) | 2011-07-31 |
| WO2010071988A8 (en) | 2011-07-21 |
| CN105859680A (zh) | 2016-08-17 |
| KR101810988B1 (ko) | 2017-12-20 |
| MX2011006795A (es) | 2011-09-26 |
| KR20110104002A (ko) | 2011-09-21 |
| CA2746831C (en) | 2013-11-26 |
| RU2546108C2 (ru) | 2015-04-10 |
| RU2011124579A (ru) | 2013-01-27 |
| US20130116312A2 (en) | 2013-05-09 |
| EP2382201A4 (en) | 2015-11-18 |
| CA2746831A1 (en) | 2010-07-01 |
| SG172340A1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074854A1 (es) | Compuestos de plasmalogenos, composiciones farmaceuticas que los comprenden, su uso para tratar enfermedades del envejecimiento, procedimiento e intermediarios para su sintesis. | |
| JP6232083B2 (ja) | 薬物送達を標的化しｓｉＲＮＡ活性を増強する化合物 | |
| JP6437968B2 (ja) | リポソームナノ粒子中で使用するための修飾薬物 | |
| Bernardi et al. | Mitochondrial energy dissipation by fatty acids: Mechanisms and implications for cell death | |
| US9163032B2 (en) | Esters of DCPLA and methods of treatment using the same | |
| Nakajima et al. | Oleic acid is a potent inducer for lipid droplet accumulation through its esterification to glycerol by diacylglycerol acyltransferase in primary cortical astrocytes | |
| ES2828717T3 (es) | Compuestos ionizables y composiciones y usos de los mismos | |
| ES2923149T3 (es) | AceFaPC para el tratamiento de enfermedades dependientes de la acetilcolina | |
| BR112016006926B1 (pt) | Uso de um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico na preparação de uma composição para a prevenção e/ou a melhora da senescência de célula ou tecido | |
| JP6568536B2 (ja) | パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法 | |
| CA3177508A1 (en) | Synthetic lipid-like materials for brain delivery | |
| ES2662123T3 (es) | Derivados de esterol y uso de los mismos para tratar enfermedades que implican células astrocíticas transformadas o para el tratamiento de hemopatías malignas | |
| WO2014162123A1 (en) | Therapeutic uses of bisphosphonates | |
| US20180339966A1 (en) | Therapeutic compounds | |
| AU2015269485A1 (en) | CKAP5-gene-silencing RNAi pharmaceutical composition | |
| AU2017272198A1 (en) | Sesame oil based injection formulations | |
| KR20240088561A (ko) | 신규한 지질 화합물 및 이를 포함하는 지질 나노입자 조성물 | |
| WO2023211934A1 (en) | Lipids, formulations, and uses thereof | |
| WO2023211940A1 (en) | Sting agonists, formulations, and uses thereof | |
| EP4262777A1 (en) | Treatment of amyotrophic lateral sclerosis using pkc activators | |
| RU2436782C1 (ru) | 2-МЕТОКСИ-4[(3aR,7aS)-3,3,6-ТРИМЕТИЛ-1,3,3a,4,5,7a-ГЕКСАГИДРО-2-БЕНЗОФУРАН-1-ИЛ]ФЕНОЛ - НОВОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА | |
| 송충길 | Evaluation of N, N, N-trimethylphytosphingosine-iodide and its liposomal delivery system for the treatment of angiogenesis and metastasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |